RXRX Dec 2024 7.000 call
| Previous close | 3.2000 |
| Open | 3.8000 |
| Bid | 3.4000 |
| Ask | 4.5000 |
| Strike | 7.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.5900 - 3.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 371 |
ZacksRecursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.
GlobeNewswireRecursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nominationBayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to inve
Barrons.comNvidia Owns These 4 Stocks. Here’s How They’re Doing.
Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way.
